We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Aug 22, we issued an updated research report on St. Paul, MN-based Ecolab Inc. (ECL - Free Report) . The company is a leading provider of water, hygiene and energy technologies and services. The stock currently carries a Zacks Rank #3 (Hold).
Ecolab had an impressive run on the bourse over the last three months, trading above the industry in terms of price performance. A glimpse at the price movement reveals that Ecolab’s shares have gained 2.7%, comparing favorably with the industry’s 1.9% decline.
Ecolab reported a stellar second quarter of fiscal 2017 result, beating the Zacks Consensus Estimate for both counts. The upside came from new business gains, better pricing, product innovation and cost efficiencies. Overall adjusted quarterly net sales were $3.46 billion, up 4% from the year-ago period. This more than offset higher delivered product costs.
For the third quarter of 2017, Ecolab projects adjusted diluted earnings per share in the range of $1.36–$1.44, compared with $1.28 a year ago. Ecolab’s considerable earnings growth despite the challenging business environment instills confidence. Additionally, the company's large base of recurring revenues, industry-leading technologies and excellent field service are significant propellers for long-term growth.
The company’s prospects in the Global Industrial and Global Institutional business segments are also bright. In the last reported quarter, sales at these segments both scaled 3%, on a year-over-year basis. Furthermore, Ecolab boasts compelling fundamentals with revenues and adjusted earnings multiplying at a rate of 4.6% and 13.7%, over the last three years.
However, on the flip side, unfavorable foreign currency and the impact of Venezuelan deconsolidation are expected to hurt earnings in the near term. Also escalating costs and expenses are weighing on its margins. Last month, a comparative study of Ecolab’s forward P/E (forward 12-month basis) multiple reflected that the stock has been quite overvalued.
Key Picks
Some better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. and Stryker Corporation (SYK - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Stryker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has climbed around 19.4% in the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 28.6% in the last six months.
Stryker Corporation has a long-term expected earnings growth rate of 10.00%. The stock has rallied roughly 12.8% in the last six months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
Image: Bigstock
Ecolab Sales Solid Amid Escalating Delivered Product Costs
On Aug 22, we issued an updated research report on St. Paul, MN-based Ecolab Inc. (ECL - Free Report) . The company is a leading provider of water, hygiene and energy technologies and services. The stock currently carries a Zacks Rank #3 (Hold).
Ecolab had an impressive run on the bourse over the last three months, trading above the industry in terms of price performance. A glimpse at the price movement reveals that Ecolab’s shares have gained 2.7%, comparing favorably with the industry’s 1.9% decline.
Ecolab reported a stellar second quarter of fiscal 2017 result, beating the Zacks Consensus Estimate for both counts. The upside came from new business gains, better pricing, product innovation and cost efficiencies. Overall adjusted quarterly net sales were $3.46 billion, up 4% from the year-ago period. This more than offset higher delivered product costs.
For the third quarter of 2017, Ecolab projects adjusted diluted earnings per share in the range of $1.36–$1.44, compared with $1.28 a year ago. Ecolab’s considerable earnings growth despite the challenging business environment instills confidence. Additionally, the company's large base of recurring revenues, industry-leading technologies and excellent field service are significant propellers for long-term growth.
The company’s prospects in the Global Industrial and Global Institutional business segments are also bright. In the last reported quarter, sales at these segments both scaled 3%, on a year-over-year basis. Furthermore, Ecolab boasts compelling fundamentals with revenues and adjusted earnings multiplying at a rate of 4.6% and 13.7%, over the last three years.
However, on the flip side, unfavorable foreign currency and the impact of Venezuelan deconsolidation are expected to hurt earnings in the near term. Also escalating costs and expenses are weighing on its margins. Last month, a comparative study of Ecolab’s forward P/E (forward 12-month basis) multiple reflected that the stock has been quite overvalued.
Key Picks
Some better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Lantheus Holdings, Inc. and Stryker Corporation (SYK - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Stryker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has climbed around 19.4% in the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 28.6% in the last six months.
Stryker Corporation has a long-term expected earnings growth rate of 10.00%. The stock has rallied roughly 12.8% in the last six months.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
See Stocks Now>>